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Abstract
Background: The incidence of and mortality from colorectal cancers (CRC) can be reduced by early detection.
Currently there is a lack of established markers to detect early neoplastic changes. We aimed to identify the copy
number variations (CNVs) and the associated genes which could be potential markers for the detection of neoplasia
in both ulcerative colitis-associated neoplasia (UC-CRN) and sporadic colorectal neoplasia (S-CRN).
Methods: We employed array comparative genome hybridization (aCGH) to identify CNVs in tissue samples of UC
nonprogressor, progressor and sporadic CRC. Select genes within these CNV regions as a panel of markers were
validated using quantitative real time PCR (qRT-PCR) method along with the microsatellite instability (MSI) in an
independent cohort of samples. Immunohistochemistry (IHC) analysis was also performed.
Results: Integrated analysis showed 10 overlapping CNV regions between UC-Progressor and S-CRN, with the 8q
and 12p regions showing greater overlap. The qRT-PCR based panel of MYC, MYCN, CCND1, CCND2, EGFR and
FNDC3A was successful in detecting neoplasia with an overall accuracy of 54 % in S-CRN compared to that of 29 %
in UC neoplastic samples. IHC study showed that p53 and CCND1 were significantly overexpressed with an
increasing frequency from pre-neoplastic to neoplastic stages. EGFR and AMACR were expressed only in the
neoplastic conditions.
Conclusion: CNVs that are common and unique to both UC-associated and sporadic colorectal neoplasm could be
the key players driving carcinogenesis. Comparative analysis of CNVs provides testable driver aberrations but
needs further evaluation in larger cohorts of samples. These markers may help in developing more effective
neoplasia-detection strategies during screening and surveillance programs.
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Background
Colorectal cancer (CRC) is the third most common form
of cancer and the second leading cause of death among
the cancers worldwide. Studies have shown that coun-
tries with medium and high human development index
(HDI) are likely to show a rise in the incidence of CRC
by 2030 [1–3]. While most sporadic CRC arise through
the adenoma-carcinoma sequence, UC-CRC arises through
inflammation-associated dysplasia-carcinoma sequence. In
either situation, the cancer develops from acquiring
hallmark genetic changes in the epithelium of the colon.
The genetic alterations that might lead to the development
of CRC in either pathway have, by tradition, been largely
categorized into chromosomal instability (CIN) and micro-
satellite instability (MSI) [4–6].
Copy number variations (CNVs) in the cancer cell
genome is one of the common mechanisms under CIN
by which the expression of genes that contribute to can-
cer development is regulated and studying this can help
in identifying tumor suppressor genes and oncogenes.
CNVs are found frequently in the healthy population
(common CNVs) too, but some of the CNVs associated
with malignancy are known to harbor bona fide cancer-
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related genes [7–12]. Although genomically altered re-
gions are very common in human cancer, it is often diffi-
cult to identify the true cancer gene in such amplicons
because of the multiplicity of genes affected [13–15].
Genome-wide studies in different types of cancer, in-
cluding CRC, have highlighted several important regions
and genes involved in human cancer development,
which have been significantly altered, by amplification or
overexpression [16–19]. Therefore, the comparative
identification of such altered regions and the genes
within those regions and their role in cancer is essential
for better understanding of the pathogenesis of cancer
and also for clinical translation.
The incidence and deaths from CRC can be reduced
by the early detection and removal of treatable neoplasia
but for the lack of established markers specific for both
established cancer and precancerous lesions [20]. Mo-
lecular stratification, combined with other strategies,
may be suitable to distinguish those with preneoplastic
changes from those with early neoplastic changes). Our
previous study has shown that CNVs are progressively
associated with the development and progression of UC
to CRC [21]. With this background, we analyzed the
CNVs involved in UC-progressors and S-CRC as com-
pared to those with nonprogressors, and validated their
role in a subset of samples by qRT-PCR and IHC tech-
niques for identification of neoplasia in two of the CRC
pathways.
Results
CNVs in Ulcerative colitis nonprogressor (UC-NP)
We found a relatively small number of copy number
variants in the UC-NP group in pooled biopsies from
high risk UC patients without any dysplasia. There were
15 CNV regions in total, encompassing 20 genes across
different chromosomes (Additional file 1: Table S1). The
copy number amplified segment in chromosome 15 was
found to be largest harboring 9 genes.
CNVs in Ulcerative colitis progressor (UC-P)
UC-P samples, comprised of pooled dysplastic and carcin-
oma biopsy samples, were analyzed against the control
samples for aberrant changes happening during the neo-
plastic changes. A total of 26 chromosomal aberrations
were found across the 16 chromosomes listed (Additional
file 1: Table S2). More number of gain regions was found
across the genome viz., 2q13, 5p13.2, 5q35.3, 5q35.2,
7q31.2-q31.31, 7q32.1, 8p23.1, 8q24.21, 8q24.22, 9p12,
10q23.2, 12p13.33-31, 14q21.1, 15q11.2, 15q13.3, 16p13.11,
16p12.3, 22q11.21, Xq21.31, Yp11.31, as compared to the
regions with loss, which were very few and smaller in
length and were spread across 3q26.1, 4q13.2, 8p11.23,
11q11, and Xp22.31. About 122 genes were found to be
embedded within these CNV altered regions.
CNVs in Sporadic colorectal cancer (S-CRC)
The S-CRC microarray data highlighted a number of
chromosomal regions encompassing protein-coding genes,
which exhibited copy number variations (Additional file 1:
Table S3). A total of 25 aberrant regions spanning 11 chro-
mosomes, containing more than 400 genes, were observed
from the S-CRC sample. Overall gains were observed in
4q34.1, 6p21.32, 8p11.23, 8p12.1-12.3, 8q24.21, 12p13.32,
12p13.31, 13q14.12, 13q21.1, 20p13 and 20q11.1-q13.33.
Loss of CNV regions was found across 4p13, 4q13.2,
5p13.2, 5q33.1, 5q35.2, 8p23.1, 8p11.23, 10q23.2, 15q11.2,
22q11.23, Yp11.3, Yp11.2, Yq11.221 and Yq11.223. We
observed a large copy number amplified chromosomal
segment on chromosome 20q harbouring 381 genes.
The smallest region was found in chromosome 4p, con-
sisting of 1000 bp CNV, encompassing a single gene
and a ‘gain’ status.
Integrative data analysis of 244 k arrays in the different
groups
A combined analysis of all the three 244 k aCGH micro-
array data highlighted some of the common and unique
CNV regions, and their characteristic behavior in differ-
ent sample groups (Fig. 1). There were 10 CNV regions
across the sample groups, which overlapped with at least
one of the sample groups. The chromosome 15 CNV
was common to all the three sample groups, with ampli-
fication in UC-P and UC-NP, and deletion in S-CRC.
Eight CNV regions were common between UC-P and S-
CRC, of which 3 regions viz., 4q13.2 (Loss), 8q24.1
(Gain) and 12p13.32 (Gain) showed the same status in
both the groups. But the CNV alteration status varied in
the other 5 common regions viz., 5p13.2, 5q35, 8p12,
8p23 and 10p regions (Additional file 1: Table S4 and
Fig. 1). By using Venny analysis, 9 genes were found to
be common between the three groups of samples, while
29 genes were common between UC-P and S-CRC
(Additional file 2: Figure S2). A total of 84 out of 122
genes were found to be unique in UC-progressors CNV
data and found to have major role in regulating import-
ant molecular functions. (Additional file 1: Table S5).
Additionally a list of miRNAs identified within the CNV
regions is shown in (Additional file 1: Table S6).
Comparison of CRC genomic profiles of CNV data vs.
TCGA data
A comparative analysis was performed between our
CNV data and data from The Cancer Genome Atlas
Project (TCGA) on sporadic CRC. A number of regions
from the TCGA data overlapped with our sample data
sets (Additional file 1: Table S7). Eight of the CNV re-
gions from our S-CRC data corresponded to the TCGA
reported CNV regions, though the CNV regions found
in our study were much smaller in length. The matching
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CNV status was almost similar except for one small re-
gion on chromosome 4 that was reported as a deletion
in TCGA data, while we found it to be amplified. In case
of UC-P, there were 6 common CNV regions between
our data and TCGA regions. Interestingly, a CNV region
on chromosome 15 amplified in UC data (both UC-P
and UC-NP), was found to be deleted in our S-CRC
group and TCGA (CRC) data. However, amplification of
CNV regions in chromosomes 8 and 12 was common in
all the three data sets (Additional file 1: Table S7).
Gene set enrichment analysis (GSEA) and Gene Ontology
and Pathway Analysis of gene lists from 244 k aCGH data
Genes from the CNV regions obtained from our 244 k
aCGH study were stratified on the basis of their known
role in cancers using the Broad Institute’s GSEA analysis.
The S-CRC data showed 6 oncogenes, 1 tumor suppres-
sor and 36 transcription factors (Additional file 1: Table
S8), while in UC-P, there were 5 oncogenes and 10 tran-
scription factors (Additional file 1: Table S9). MYC and
CCND2 were the two common genes in UC-P and S-
CRC, as highlighted in GSE analysis. We performed a
gene ontology search for common biological processes
affected by these genes using the DAVID tool. The sig-
nificant gene ontology terms under biological process of
S-CRC and UC-P groups are highlighted (Additional file
2: Figure S3), with cell cycle control being a common
term enriched (p < 0.05) in these groups. The significant
targeting of KEGG pathways agreed well with results
showing gene sets from CNVs of both S-CRC and UC-P
to target some of the major cancer pathways. CNV genes
from UC-P were significantly involved with MAPK and
Wnt signaling pathways, whereas S-CRC genes were sig-
nificantly matched with TGF-beta signaling pathway
(Additional file 1: Table S10).
Quantitative RT-PCR analyses
MSI and CIN status
The normal, UC-P and UC-NP samples analyzed were
microsatellite stable (MSS). In the S-CRN group of sam-
ples, 16/98 (16.3 %) samples showed MSI, out of which
4/18 (22.2 %) were in adenomas and 12/80 (15 %) were
in adenocarcinomas. Out of 16 MSI positive samples,
only 4 did not show any chromosomal instability for the
markers analyzed in our qRT-PCR study.
Validation of six genes, MYC, MYCN, CCND1,
CCND2, EGFR and FNDC3A across the three major
groups of samples are shown in (Additional file 2: Figure
S4, S5 ) and Table 1. C-MYC (22.5 %) and FNDC3A
(20.6 %) were significantly amplified in S-CRN as compared
to that of normal samples. In case of UC-HR samples only
C-MYC (16.1 %) gene was significantly amplified when
compared to normal. FNDC3A in S-CRN was significantly
amplified as compared to both normal and UC-HR samples
implying its specificity in sporadic CRC pathway.
Gene to gene interaction, correlation and functional
pathway analysis
The associations between the raw copy number score of
each sample across all the 6 genes was used to measure
the correlation between any two genes (Additional file 2:
Figure S4). Raw copy numbers of EGFR and CCND1
was the only positive significant correlation in UC-HR
(r = 0.430, p < 0.05), while with the highest positive correl-
ation in S-CRN group (r = 0.372, p < 0.01) (Table 2). The
6-gene genomic instability marker panel was designed as a
signature that might be involved in important mecha-
nisms of tumor genesis and progression. Towards this,
functional pathway analysis for this panel was performed
based on database of molecular interactions reported in
the literature using Ingenuity Pathway Analysis (IPA) and
Fig. 1 Genome wide chromosomal abnormalities identified in UC-NP (blue circle) samples, UC-P (green square) samples and S-CRC (orange
triangle) samples. The heat map is the representative of gene density across each chromosome
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using cBioPortal, which showed strong interactions
between cancer genes and the pathways (Additional
file 2: Figure S6).
Sensitivity and specificity for the gene panel
The chromosomal instability signature using the current
6-marker panel was observed in 54/98 (54.1 %) of spor-
adic colorectal neoplasia patients without MSI. In the
same S-CRN group of patients, combination of this
panel along with MSI increased the neoplasia detection
up to 58.2 %. In case of UC-HR samples, 9/31 (29 %) of
the samples showed chromosomal instability (Table 3
and Additional file 1: Table S11).
Immunohistochemistry analyses
For IHC scoring of p53 and CCND1 proteins, the inten-
sity of nuclear staining was considered. For Ki-67, only
the percentage of positively stained nuclei was assessed,
as the intensity was similar in all positive nuclei. Mem-
branous staining was assessed for ERBB2, whereas for
EGFR both membranous and cytoplasmic staining was
scored. For C-MYC, AMACR and FNDC3A genes only
cytoplasmic staining was assessed.
When analyzed together, the 8 markers the typically
showed no or weak immunostaining in the nonprogres-
sor tissues, while the immunostaining was frequently
moderate to strong in dysplastic or cancerous tissues in
UC-HR group (Table 4 and Additional file 2: Figure S7).
p53 and CCND1 showed significant immunostaining
from early high risk stage to neoplastic change. AMACR
and EGFR were more specific for neoplastic changes in
both UC-HR and S-CRN. C-MYC and ERBB2 were
expressed at lower intensity in both UC-P and S-CRN
tissue samples. In the proliferative marker Ki67 ex-
pression analysis a significantly higher proliferation
index (p < 0.05) for both UC-P and S-CRN groups was ob-
served as compared to that of UC-NP (Additional file 2:
Figure S8). FNDC3A, a cytoplasmic protein, was found
strongly overexpressed in all sporadic adenocarcinoma
samples. In case of UC-NP and UC-P, 55 % and 88.9 % of
the samples respectively showed positive immunostaining
for FNDC3A.
Discussion
From our previous study we observed that CNVs are
progressively associated with the development and pro-
gression of different stages from UC to CRC [21]. The
present study has identified genome-wide altered CNV
regions in tissues of UC-progressors, in comparison with
S-CRC. An attempt was made to create a panel of
markers, including two genes (C-MYC and CCND2) com-
mon to both the pathways, along with other correlated
genes, which was evaluated in a larger cohort of either
condition for their usefulness in the detection of neoplasia
Table 1 The summary of quantitative real-time PCR results for potential six candidate oncogenes amplification in study group of
samples
Gene S-CRN n = 102 UC-CRN n = 31 Controls n = 30 1p-value 2p-value
MYC
Amp n (%) 23 (22.5 %) 5 (16.1 %) 0 0.004 0.05
Nor n (%) 79 (77.5 %) 26 (83.9 %) 30 (100 %)
MYCN
Amp n (%) 16 (15.7 %) 2 (6.5 %) 1(3.3 %) NS NS
Nor n (%) 86 (84.3 %) 29 (93.5 %) 29 (96.7 %)
EGFR
Amp n (%) 21 (20.6 %) 1 (3.2 %) 2 (6.7 %) NS NS
Nor n (%) 81 (79.4 %) 30 (96.8 %) 28 (93.3 %)
FNDC3A
Amp n (%) 21 (20.6 %) 2 (6.5 %) 1 (3.3 %) 0.04 NS
Nor n (%) 81 (79.4 %) 29 (93.5 %) 29 (96.7 %)
CCND1
Amp n (%) 10 (9.8 %) 3 (9.7 %) 0 NS NS
Nor n (%) 92 (91.2 %) 28 (91.3 %) 30 (100 %)
CCND2
Amp n (%) 13(12.7 %) 3 (9.7 %) 1 (3.3 %) NS NS
Nor n (%) 89 (87.3 %) 28 (91.3 %) 29 (96.7 %)
Amp: amplification of gene (copy number >2); Nor: normal gene copy (copy number ≤2);n = number of samples;1p-value: statistical comparison between
S-CRN vs Control; 2p-value: statistical comparison between UC-CRN vs Control; NS: statistically not significant (p > 0.05). S-CRN group is comprised of 98
samples and 4 cell lines
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in both CRC conditions. The four noteworthy genes from
the above qRT-PCR study were combined complimenta-
rily with four reported markers in CRC and were together
analyzed for their expression in a subset of both sporadic
and UC neoplasia samples. The current study provides an
overview of information on genomic aberrations present
in UC associated and sporadic neoplasia and possible
markers of importance of disease and molecular patho-
physiology. These results can possibly help to better
understand the CNVs and the genes involved in the
adenoma-carcinoma and dysplasia-carcinoma progression.
The current study is from a region known for its lower
prevalence of both UC and CRC, but showing an in-
creasing trend in recent times, although the exact preva-
lence of these diseases is contentious [22–25]. A recent
estimation highlighted an increase of CRC by 2.7 % in
developing countries like India [1–3]. But clinical and
molecular reports on S-CRN and UC-CRN are scarce
from this region. The present study is one of its first
types to study integrating aCGH, qRT-PCR and IHC
analyses of neoplastic changes in both colitis-associated
and sporadic neoplasms for identifying major genomic
alterations across the two pathways of CRC develop-
ment. The bioinformatics-based enrichment analysis
along with the comparison with TCGA data showed
many overlapping CNVs reinforcing the importance of
these altered regions and genes associated with them.
Reports on the use of advanced microarray techniques
for UC-CRC are uncommon and studies are lacking on
the comparative analysis of CNVs in UC and S-CRC.
Using aCGH, the present study has demonstrated im-
portant unique and common CNVs associated with neo-
plasia progression in both UC and sporadic neoplastic
pathway. One of the comparative studies by Aust and
colleagues [2000] on UC and S-CRC using chromosomal
CGH highlighted differences in the frequency and timing
of individual alterations suggesting various pathways that
operate between the two groups [26]. Earlier studies
found that losses in 8p, 15q and 18q and gains in 8q,
13q and 20q were the most common copy number
Table 2 Correlation coefficients of gene copy number between six amplified genes in S-CRN and UC-CRN tissues
Pearson Correlation coefficients and P-values were determined as described in the materials and methods. Above the diagonal indicates S-CRN samples tissues
(n = 98) and below the diagonal indicates UC-CRN samples (n =31).*. Correlation is significant at the 0.05 level (2-tailed). **. Correlation is significant at the
0.01 level (2-tailed)
Table 3 Analysis of significance of gene amplification using
6-gene marker panel
Controls n = 30 S-CRN n = 98 UC-CRN n = 31
0 marker amplified 24 (80 %) 45(45.9 %) 22 (71 %)
≥1 marker amplified 6 (20 %) 53(54.1 %)*# 9 (29 %)
*p = 0.001: p-value comparing S-CRN with control; # p = 0.02: p-value comparing
S-CRN with UC-CRN
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alterations associated with the progression of colorectal
adenoma to carcinoma [26–30]. In the current analysis,
we found 13q and 20q amplifications in S-CRC alone,
but 8q amplifications were present in both UC-P and
S-CRC samples. In comparison with S-CRC data, UC-P
had noticeably smaller CNV regions with more gain
statuses (for example, in chromosomes 7, 8, 12 and 22).
Interestingly 15q CNV was one of the common CNVs
between the 3 sample groups amplified in UC samples,
but deleted in S-CRC. Common CNV regions and
genes emerged from integrated analysis of UC-P and S-
CRC suggests a common molecular function is regu-
lated in neoplastic epithelial cells. The chromosomal 8q
and 12p regions comprises of important functional
genes such as C-MYC and CCND2 oncogenes and may
drive sporadic as well as inflammation associated car-
cinogenesis. Bioinformatics analysis and other studies
too have highlighted the importance of these CNVs and
genes [11, 31]. Thus, these results may help broaden
our understanding of the inter-related molecular path-
ways in the two conditions.
Studies on whole genome aberrations have been
attempted to identify and test potential markers for transla-
tion, since few markers are currently being recommended
for use in the clinical practice [32]. The cancer genome
atlas project (TCGA) is among the major initiative in this
aspect and has reported a comprehensive genome-scale
analysis of genetic variations across 276 CRC samples [29].
The overlapping analysis of our aCGH based CNV results
with TCGA data has shown many similar CNV regions
and these CNVs can be tested across populations.
Much effort has also been devoted to the development
of panel of markers based on genetic and epigenetic
alterations in different cancers [33, 34]. We attempted to
establish a panel of markers from the CNV regions and
validated the same in our patient’s cohort using qRT-
PCR. Towards this effort, a 6-gene genomic instability
signature for neoplastic changes was designed and vali-
dated in both the colorectal cancer types. The 3 genes
(C-MYC, CCND2 and FNDC3A) were selected from our
data and together with the previously published genes
(MYCN, CCND1 and EGFR), we generated a panel of 6
genes for validation. Functional pathway enrichment
analysis was carried out based on curated database using
Ingenuity Pathway Analysis and cBioPortal using
TCGA-CRC data. The current panel, considering alter-
ations in at least one marker, was efficient in detecting
neoplastic changes in more than 50 % of the samples in
S-CRC but was comparatively less in UC-neoplastic
samples. Combination of MSI and qRT-PCR panel did
Table 4 Staining patterns of each immunohistochemical marker in sample groups of non-progressor or with progressors and
sporadic colorectal neoplasia
Genes UC-NP n = 20 UC-P n = 18 S-CRN n = 14 1p-value 2p-value 3p-value
p53 + 7 (35 %) 16 (89 %) 9 (64 %) 0.0009 0.1 0.1
<50 % 2 (28.6 %) 1 (6.2 %) 1 (11.1 %)
>50 % 5 (71.4 %) 15 (93.8 %) 8 (89 %)
CCND1 + 12 (60 %) 17 (94 %) 14 (100 %) 0.02 0.01 NS
<25 % 9 (75 %) 5 (29.4 %) –
>25 % 3 (25 %) 12 (70.6 %) 14 (100 %)
AMACR + – 9 (50 %) 6 (43 %) – – –
<5 % – 2 (22.2 %) –
>5 % – 7 (77.8 %) 6 (100 %)
EGFR + – 10 (56 %) 7 (50 %) – – –
<5 % – 2 (20 %) 1 (14.3 %)
>5 % – 8 (80 %) 6 (85.7 %)
C-MYC + 4 (20 %) 10 (56 %) 7 (50 %) 0.04 0.1 NS
<5 % 2 (50 %) 1 (10 %) 2 (28.6 %)
>5 % 2 (50 %) 9 (90 %) 5 (71.4 %)
ERBB2 + 2 (10 %) 4 (22 %) 6 (43 %) NS 0.04 NS
<5 % 2 (100 %) – 2 (33.3 %)
>5 % – 4 (100 %) 4 (66.7 %)
FNDC3A + 11 (55 %) 16 (88.9 %) 14 (100 %) 0.032 0.004 NS
The number and percentage of patients with a positive immunostaining according to staining intensity and the percentage of stained cells in these
patients.1p-value: statistical comparison between UC-NP vs UC-P; 2p-value: statistical comparison between UC-NP vs S-CRN; 3p-value: statistical comparison
between UC-P vs S-CRN
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not significantly improve the sensitivity of detection. In
correlation analysis, we found that EGFR and CCND1
raw copy number values are positively correlated with
neoplastic changes in both UC and S-CRN samples.
There are several reports on the gene amplifications in
CRC that has been correlated to gene expression [13, 14,
35–37]. We tested by IHC using 8 markers which is a
combination of previously reported markers and from
our qRT-PCR study. Results conclude that p53, CCND1,
EGFR, C-MYC and FNDC3A were overexpressed more
than 50 % of the time in S-CRN samples. Interestingly in
UC-HR samples, it was observed that p53 and CCND1
were significantly expressed at higher frequency com-
pared to tissues from preneoplastic stages, while C-MYC
and ERBB2 were expressed at very low frequency. EGFR
and AMACR expression was more specific towards neo-
plastic changes and showed a linear relationship with in-
creasing disease frequency.
Fibronectin type III domain containing 3A (FNDC3A)
gene is shown to be involved in major biological func-
tion of cell-cell adhesion and is one of the genes from
the widely reported 13q CNV region in S-CRC. How-
ever, very little is known about the role of this gene in
cancer. FNDC3A gene showed amplified copy number
status in both aCGH and qRT-PCR, and overexpressed
in tissue samples of S-CRC. The functional significance
of FNDC3A warrants further study in adenocarcinoma.
In accordance with our previous findings on p53 muta-
tional analysis, to the current IHC results suggest that
the p53 pathway is perhaps an early event and Wnt-
pathway regulated changes in C-MYC are in the later
phase of colitis associated carcinogenesis [38]. In clinical
practice, assessment of the expression of these markers
may help to identify patients with risk of neoplasia,
thereby supporting the surveillance strategies and therapy.
Pooled sample-based analysis has been recognized as a
cost-effective alternative approach for filtering genetic
variance of higher significance, though chances of miss-
ing less frequent CNVs exist [39, 40]. The success of
sample pooling based arrays depends upon reducing the
overall pooling error however, errors due to array spe-
cific variability remains. The important and major CNV
regions (e.g. 8q, 13q, 20q amplifications) reported in this
study across the CRC genome have been retained even
after the pooling. Sampling biases due to tissue hetero-
geneity and multifocality of epithelium have been the
limiting factors in CRC molecular analysis [40]. MSI and
CIN analysis by qRT-PCR could have been affected by
these above factors. Another limitation of these assays is
that their detection thresholds usually need clonal expan-
sion and broad field effects of the targeted cell population
being tested [41]. The number of patients in each group
was relatively low, which requires a careful interpretation
of the results. Similarly in the IHC study, the degree of
immunoreactivity of each antibody may frequently hetero-
geneously distributed throughout the tissue sample [42].
To avoid selection bias during the scoring, we selected the
area with the strongest immunoreactivity in each tissue
sample [42, 43]. In order to predict the prognosis and
therapeutic outcome, series of studies have established
biomarker panels for S-CRC. However, consensus on the
suitable biomarkers for early diagnosis remains to be
established [14, 44]. In the current study, we have
attempted to simultaneously analyze two CRC related
using panel of markers to aid in further understanding of
molecular pathogenesis. The study has integrated some of
the well-known marker genes along with the relatively
new loci from the current study in the analysis as a group
and highlighted their importance in early phases of cancer
development and detection. These may help in under-
standing and targeting the different stages of CRC devel-
opment in UC patients who are on continuous follow-up
for their disease evaluation. The surveillance program re-
mains cumbersome and addition of these markers along
with clinical follow up to increase the efficiency of neopla-
sia detection can lead to better and successful screening
strategies. Of significance is that this is the only report
from India and among a very few elsewhere, to have
comparatively analyzed and validated CNVs and the
genes together and the expression patterns of markers
in both UC and sporadic colorectal neoplasia.
Conclusion
Our aCGH analysis demonstrated that colitis associated
and sporadic colorectal carcinomas do contain a varied
level of CIN in the form of CNVs and are common to
CRC pathways. Overlapping of our data with TCGA-
CRC data indicated common CNVs across the popula-
tions. The marker panel based validation study by using
qRT-PCR and IHC may help to delineate choice of
markers from CNV regions for identification of CRC.
Reproducibility testing with a larger cohort and longitu-
dinal analyses over time is required to assess the role of
CNVs as potential markers. Comparative CNV analysis
on colitis associated and sporadic cancer genomes has
provided the testable loci for possible aberrant driver
events. Using advanced colonoscopic techniques to tar-
get the abnormal areas for neoplasia detection followed
by targeted molecular analysis may help in screening




Study was approved by the Kasturba Hospital Ethics
Committee (KHEC No.159/07), Manipal. All the patients
provided written informed consent before participation.
Tissue samples were obtained from biopsy of the patients,
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further divided into following groups UC-nonprogressors
(UC-NP): 20 UC patients with high risk but without any
dysplasia, UC-progressors (UC-P): 08 patients with dys-
plasia or cancer, and sporadic colorectal cancer (S-CRC):
20 patients. A pool of DNA from 20 (10 male and 10 fe-
male) endoscopically and histopathologically normal colon
were used as the control samples for all the arrays. For all
DNA based assays, DNA was isolated from the tissue
using phenol-chloroform method. To search for genetic
variations, the experimental design comprised of the
hybridization of tissue DNA samples from above men-
tioned groups of patients against a control pool consisting
of the non-tumor tissue.
For validation by qRT-PCR study, UC-HR group com-
prised of thirty-one patients with UC at risk of associated
colorectal neoplasia (≥7 years of extensive colitis or
≥10 years of left-sided colitis) were included in the ana-
lysis. These samples were further classified as UC progres-
sor (n = 14) and UC non-progressor (n = 17) based on the
presence or absence, respectively, of neoplastic changes.
The sporadic colorectal neoplasia samples were collected
through colonoscopy from 98 patients, of whom 80 were
adenocarcinomas and 18 were adenomas. The control
group consisted of DNA extracted from 15 men and 15
women subjects with no organic colonic disease (Colonos-
copicaly and histopathologically confirmed) (Table 5).
For IHC-based expression analysis in UC-HR, group
comprised of 38 samples. Out of these 18 were progres-
sor and among these 18 samples LGD was found in 5,
HGD in 9 and UC associated CRC in 4 samples. The
comparative S-CRN group comprised of 14 patient sam-
ples out of which 4 were primary colorectal cancer and
10 adenoma samples. For IHC experiment, each sample
was confirmed with initial Hematoxylin and Eosin
(H&E) grading.
Those with S-CRN underwent endoscopic biopsies
from affected and normal areas for histology and mo-
lecular analysis. The diagnosis of both UC and CRN was
made according to established criteria, including clinical
symptoms, colonoscopy and histopathology. Human
colorectal cancer cell lines CACO-2, COLO-205, HT-29
and HCT-15 were obtained from National Centre for
Cell Science (NCCS, India) and DNA extracted from
them was used in the initial analysis. The overall study
design has been elucidated in (Additional file 2: Figure
S1). Briefly, to identify of genome wide CNVs contribut-
ing to both UC associated neoplasia and sporadic CRC
development, we performed 244 k aCGH experiment.
The aCGH results were analysed for common and
unique CNVs to both the samples and enrichment of
CNVs for functional annotation using bioinformatics
tools that overlap with TCGA data and literature was
performed. Three genes (C-MYC, CCND2 and FNDC3A)
were selected from our data and together with previ-
ously reported (MYCN, CCND1 and EGFR) genes were
validated using Taqman CNV based qRT-PCR assay on
UC-high risk, sporadic colorectal neoplasia and com-
pared against control samples. Subsequently, the four
genes (C-MYC, CCND1, EGFR and FNDC3A) from the
above qRT-PCR study were assessed along with four
previously reported markers (p53, AMACR, ERBB2 and
Ki67) for their expression by IHC in both UC and spor-
adic CRC sample.
Microarray platform
aCGH was performed using the Agilent Human Genome
Microarray Kit (Agilent Technologies, Santa Clara, CA)
microarrays. This array contained 236,381 distinct bio-
logical 60-mer oligonucleotide probes, with 1,000 bio-
logical triplicates and 5,045 controls spanning coding
and non-coding genomic sequences with median probe
spacing of 7.4 and 16.5 kb, respectively. The average
probe spacing was 6.4 kb was calculated by dividing total
repeat-masked genome size by total microarray features.
The probe sequences and gene annotations were based
on NCBI Build 36.1 of the human genome and UCSC
version hg18 released in May 2006.
Microarray analysis
Copy number variation (CNV) analysis of UC-
nonprogressor, UC-progressor and sporadic CRC was
performed using Agilent high-density 244 K microarray.
Briefly, DNA samples were sheared using a cycle of 15 s
‘on’ and 15 s ‘off ’ for 15 min in an ultrasonic processor
(Thomas Scientific, NJ, USA) with a 2 mm probe with
amplitude set at 40. The purified sheared DNA was
differentially labeled, test samples DNA (test genome)
with fluorescent Cy5 and the pooled normal reference
(control genome) DNA with Cy3 dyes. Hybridization,
washing and scanning of the arrays were performed
Table 5 Clinical details of the samples in the quantitative real-time PCR validation study
Sample N Male:Female Median Age (range) in years
Controls Normal 30 15:15 52.5 (18–72)
Sporadic Colorectal neoplasia (S-CRN) Adenoma 18 16:02 56.5 (19–79)
Adenocarcinoma 80 51:29 55 (07–88)
Ulcerative colitis associated colorectal neoplasia (UC-CRN) UC-Nonprogressor 17 10:07 54 (18–68)
UC-Progressor 14 08:06 49.5 (20–69)
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according to the manufacturer’s protocol. Feature ex-
tracted data was analyzed with Genomic Workbench
v5.0 software (Agilent Technologies, CA, USA) using
ADM-2 aberration detection algorithm (threshold 5.0)
and visual inspection of the log2 ratios (±0.25) [45].
Gene enrichment, gene ontology and pathway analysis
were carried out using GSEA, DAVID, PANTHER,
cBioPortal and KEGG bioinformatics tools.
Multiplex PCR based Microsatellite Instability (MSI)
Analyses
Microsatellite instability (MSI) status was examined
using 5 microsatellite markers (National Cancer Insti-
tute, Bethesda Panel). The assay was carried out using
the primer sequences and the corresponding fluorescent
dyes and PCR as described elsewhere [46]. In brief,
multiplex PCR was performed in a Veriti thermocycler
(Applied Biosystems, Foster City, CA) using the following
cycling conditions: 95 °C for 2 min, followed by 30 cycles
of 94 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, with a
final 45 min, 60 °C extension to aid non-template adenine
addition. The PCR products were analyzed using ABI
3130 Genetic Analyzer (Applied Biosystems, Foster City,
CA) along with GS500LIZ size standard according to the
manufacturer’s instructions. The generated data were ana-
lyzed using Genemapper v.4.0 (Applied Biosystems, Foster
City, CA). If there was a peak shift or presence of abnor-
mal alleles at zero, one or more microsatellite loci tested
compared with the normal control DNA from the same
patient, the samples were graded as microsatellite stable
(MSS) or microsatellite instable (MSI) respectively.
Copy number determination by quantitative real-time
PCR (qRT-PCR)
The number of copies of C-MYC, CCND2 and FNDC3A
genes from our data were combined with their corre-
lated interacting partners MYCN, CCND1 and EGFR
genes (these genes were found to be within the cut off
log2 ratios in our aCGH data) in tumor cell lines and
tumor tissue samples from cancer patients was deter-
mined by quantitative real time polymerase chain reac-
tion (qRT-PCR). TaqMan® copy number assays (Applied
Biosystems, Foster City, CA) were applied and the
details of the genes are listed in (Additional file 1: Table
S12). These assays were performed on the 7500 Fast Real
Time PCR system with Sequence Detection System v2.4
(Applied Biosystems, Foster City, CA, USA) software.
Amplification reaction mixtures (10 ul) for each target
gene contained template DNA (10 ng), final 1x concen-
tration of TaqMan® universal master mix, TaqMan® copy
number assay reagent, and TaqMan® copy number refer-
ence assay (RNAseP) in a 96-well plate. The cycling con-
ditions used were 10 min at 95 °C, followed by 40 cycles
of 15 s at 95 °C and 60 s at 60 °C. After running each
experiment in triplicates, data files containing the sample
replicate Ct values for each reporter dye were exported
from the real-time PCR instrument software into Copy
Caller software v.1, which calculates each sample copy
number values based on relative quantitation (compara-
tive Ct method).
Immunohistochemistry (IHC) analysis
The four noteworthy genes C-MYC, CCND1, EGFR and
FNDC3A from the above qRT-PCR study were com-
bined with four reported markers p53, AMACR, ERBB2
and Ki67 (these genes were found to be within the cut
off log2 ratios in our aCGH data) in CRC (Additional file 1:
Table S13). Sections (5–7 micron thick) from formalin-
fixed, paraffin-embedded tissue samples were applied to
poly-L-lysine coated slides. The sections were dewaxed in
xylene and rehydrated and an antigen retrieval step was
done. After antigen retrieval by microwaving, immuno-
staining was performed using the biotin–streptavidin–per-
oxidase method. Counterstaining was carried out with
hematoxylin. Immunostaining for all the antibodies was
assessed according to the intensity of staining and divided
into four categories: negative (-), weak (+), moderate (++),
or strong (+++), with moderate or strong IHC staining
being regarded as positive. For staining frequency of these
antibodies, the number of positive (moderate or strong)
cells were expressed as the percentage of the total number
of cells per high-power field and categorized as 5 %–25 %,
25 %–50 %, 50 %–75 %, and >75 %.
Statistical analysis
Statistical significance was defined by P-values of ≤ 0.05.
Correlations between copy numbers of the six amplified
genes were calculated using Spearman’s rank correlation
coefficient (r). Expression patterns of the individual IHC
markers were compared between patients with progres-
sion to advanced neoplasia and those without progres-
sion and other subgroups using Fisher’s exact test or
chi-square test, as appropriate. Statistical analyses were
carried out using SPSS 15.0 (IBM) and GraphPAD InStat
(California, USA) software.
Additional files
Additional file 1: Table S1. CNVs found in UC-nonprogressor group
(UC-NP) group 244 k genomic aberration report. Table S2. CNVs found in
UC-progressor (UC-P) group 244 k genomic aberration report. Table S3.
CNVs found in S-CRC group 244 k genomic aberration report. Table S4. List
and details of the overlapping CNV regions between the three of the study
sample groups (S-CRC, UC-P and UC-NP). Table S5. List of unique in UC-
progressors genes from CNV data. Table S6. List of miRNAs overlapping to
uniquely shared CNV regions of different sample groups. Table S7. Com-
parative analysis of all CNVs observed in different sub-groups with the data
from The Cancer Genome Atlas Network (TCGA) project for CRC. Table S8.
Gene set enrichment analysis (GSEA) for S-CRC group CNV associated genes.
Table S9. Gene set enrichment analysis (GSEA) for UC-P group CNV
Shivakumar et al. BMC Cancer  (2016) 16:271 Page 9 of 11
associated genes. Table S10. The functional KEGG pathways enriched
with genes located on the chromosomal segments with copy number alter-
ations in S-CRC and UC-P samples. Table S11. Prediction accuracy of colorectal
neoplasia using the 6-gene panel instability signature along with MSI.
Table S12. Details of TaqMan CNV assays used in the microarray validation
study. Table S13. Details of antibodies and staining conditions used for
Immunohistochemistry (IHC). (PDF 398 kb)
Additional file 2: Figure S1. Overall workflow and design of the study.
Figure S2. Common genes found associated with CNVs in UC non-
progressor, UC progressor and sporadic colorectal cancers. Figure S3.
Enrichment in biological process (GO analysis) of the gene from S-CRC
and UC-P samples 244 k aCGH data. X-axis: number of genes involved in
the given function and Y-axis: biological function the genes are involved.
Figure S4. Results from the screening of gene CNVs (amplification and
deletion) in subgroups of sporadic and ulcerative colorectal neoplasm
samples in our validation panel of markers by qRT-PCR method.
(Abbreviations used are as given earlier). Figure S5. Clustering of
qRT-PCR data using 6 genes and 163 samples of different groups.
The relative copy number for each gene was plotted against different
sample groups from the current study. Figure S6. Summary of In-
genuity Pathways Analysis (IPA) for the role and interaction of the 6
genes markers panel. Figure S7. Results of immunohistochemistry
analysis carried out on UC associated and sporadic colorectal cancer
samples for various proteins; representative images are for A: p53 B:
Cyclin D1; C: AMACR; D: EGFR; E: C-MYC; F: ERBB2; G: Ki67; H:
FNDC3A. Figure S8. Box plot illustrating percentage of Ki-67 positive
cells in different sample groups of the current study: ulcerative colitis-non
progressor (UC-NP) group, ulcerative colitis- progressor (UC-P) group and
sporadic colorectal neoplasia (S-CRN) group. (PDF 551 kb)
Abbreviations
aCGH: array comparative genome hybridization; CNVs: copy number
variations; IHC: immunohistochemistry; MSI: microsatellite instability; S-
CRC: sporadic colorectal cancer; S-CRN: sporadic colorectal neoplasia; S-
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